Cytosorbents Corporation

{{Short description|American medical technology company}} {{Infobox company | name = CytoSorbents Corporation | traded_as = {{NASDAQ|CTSO}}<br />Russell 2000 Component | logo = | logo_size = | logo_alt = | logo_caption = | logo_padding = | image = | image_size = | image_alt = | image_caption = | native_name = | native_name_lang =  | former_name = | type = Public | industry = Critical care | founded =  | founder =  | hq_location = | hq_location_city = Princeton, New Jersey | hq_location_country = US | area_served =  | key_people = | num_employees = 160 | products = CytoSorb | brands = | services = | revenue = US$ 41.0 Mio. (2020)<ref>{{cite web|url=https://cytosorbents.com/cytosorbents-announces-2020-financial-and-operational-results/ |title=CytoSorbents Announces 2020 Financial and Operational Results |date=9 March 2021 |publisher=cytosorbents.com |accessdate =28 October 2021}}</ref> | owner =  | website = {{url|https://cytosorbents.com/}} }}

'''CytoSorbents Corporation''' is a publicly traded company located in Princeton, New Jersey.<ref>{{cite web|title=CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance|url=https://finance.yahoo.com/q?s=ctso|publisher=YAHOO Finance|access-date=9 April 2014}}</ref><ref>{{cite web|title=CTSO stock quote – CytoSorbents Corporation stock price – NASDAQ.com|url=http://www.nasdaq.com/symbol/ctso|publisher=NASDAQ|access-date=9 April 2014}}</ref><ref>{{cite web|title=CTSO SEC Filings|url=https://finance.yahoo.com/q/sec?s=ctso|publisher=YAHOO|access-date=9 April 2014}}</ref>

CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011<ref>{{cite web|url=http://www.otcequity.com/?p=932|title=With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval|publisher=OTC Equity|access-date=9 April 2014}}</ref>) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.<ref>{{cite web|last=Baum|first=Stephanie|title=Blood purification device for ICU patients seeks to control cytokine storm|date=24 May 2013|url=http://medcitynews.com/2013/05/blood-purification-device-for-icu-patients-seeks-to-treat-root-cause-of-sepsis/|publisher=Med City News|access-date=2013-05-24}}</ref><ref>{{cite web|title=Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy|url=http://www.artificial-organs.com/article/septic-shock-secondary-to---hemolytic-streptococcus-induced-necrotizing-fasciitis-treated-with-a-novel-cytokine-adsorption-therapy|archive-url=https://archive.today/20140607164413/http://www.artificial-organs.com/article/septic-shock-secondary-to---hemolytic-streptococcus-induced-necrotizing-fasciitis-treated-with-a-novel-cytokine-adsorption-therapy|url-status=usurped|archive-date=June 7, 2014|publisher=The International Journal of Artificial Organs|access-date=6 May 2014}}</ref>

The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis.<ref>{{Cite web|url=https://www.massdevice.com/spectral-medicals-toraymyxin-fails-pivotal-trial/|title=Spectral Medical's Toraymyxin fails pivotal trial|website=MassDevice|date=3 October 2016|language=en-US|access-date=2020-02-28}}</ref> The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy.<ref>{{Cite web |url=https://literature.cytosorb.com/ |title=Cytosorb Literature Database |access-date=2020-12-16 |archive-date=2021-01-18 |archive-url=https://web.archive.org/web/20210118220623/https://www.literature.cytosorb.com/ |url-status=dead }}</ref> Clinicaltrials.gov is giving an overview over running research projects.<ref>{{cite web | url=https://clinicaltrials.gov/ct2/results?term=cytosorb&Search=Search | title=CTG Labs - NCBI }}</ref>

CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.<ref>{{cite web|title=DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents|date=7 August 2012|url=http://globalbiodefense.com/2012/08/07/darpa-dialysis-like-therapeutic-program-award-3-8m-to-cytosorbents/|publisher=Global BioDefense|access-date=9 April 2014}}</ref> The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.<ref>{{cite web|title=CTSO Awarded Ph II U.S. Army Grant|url=http://www.zacks.com/stock/news/83460/ctso-awarded-ph-ii-us-army-grant|publisher=Zacks|access-date=9 April 2014}}</ref><ref>{{cite web |title=CytoSorbents Corporation |url=https://growjo.com/company/CytoSorbents_Corporation |website=Growjo |access-date=19 November 2020}}</ref>

== References == {{reflist|2}}

Category:Companies based in New Jersey Category:Companies listed on the Nasdaq Category:Medical technology companies of the United States